We're looking forward to attending next week's #NASHTAG2021 conference, where we will present data from a Phase II clinical trial of HTD1801 in patients with #NASH and Type II #Diabetes. Stay tuned & follow Adrian Di Bisceglie for updates. nash-tag.org

Pleased to be attending #2021NASHTAG in person in beautiful Park City UT. My first live conference in more than a year! So great to see friends and colleagues again

Y’all, our #COVID ICU unit is full. All of our ICUs are full. All of our ICU teams are flooded. Our ED is packed. We are turning away hospital transfers because there isn’t room. The #DeltaVariant is real. Masks work. Vaccines are safe and effective. Please get your vaccine!

Excited to see our recent publication highlighted as a Featured Article on Nature Communications! Read more about Phase II results of HTD1801 in patients with #NASH and #diabetes in this paper by Adrian Di Bisceglie et al: ow.ly/CxKN50GdYYo

Thanks ⁦Adrian Di Bisceglie⁩ , Drs. Bruce Luxon & Jason Taylor for organizing a memorable retirement party for Dr. Bruce Bacon. It was a great opportunity to celebrate a brilliant career and legacy of Dr. Bacon ⁦SLU Medicine⁩ ⁦SLU Hospital⁩ ⁦SLUCare Physicians⁩ ⁦SLU Gastroenterology & Hepatology⁩

Ask anyone with a chronic illness: It takes long-term patience to be a long-term patient. Read more about the #PSC experience on the @PSCPartners blog. #PSCAware #livertwitter ow.ly/Wv6Y50GAOZY

How are we hoping to help #PSC patients manage their chronic liver condition? By developing a well-tolerated drug for the difficult-to-treat #raredisease, which currently has no approved therapy. Check out the latest clinical trial results: ow.ly/x4fa50GAP2q #PSCAware

New Phase II data is coming! We're excited to be presenting the latest clinical findings in our evaluations of HTD1801 in patients w/ primary sclerosing cholangitis (#PSC) & #NASH at this month's #TLMdX Liver Meeting. Stay tuned for details. #livertwitter ow.ly/F7LN50GGboQ

Summary slide of NAFLD screening pathways by Quentin M. Anstee ; clear that 2 step screening strategy important. #TLMDx #LiverMtg21 #LiverTwitter

More HTD1801 #PSC results: 18 weeks of treatment by those previously exposed to UDCA improved biochemical markers of cholestasis & liver injury. Check out our #TLMdX poster presentation (1267) for details. AASLD #livertwitter ow.ly/p23e50GMsg0

More HTD1801 #NASH results: 18 weeks of treatment w/ Berberine Ursodeoxycholate in subjects w/ NASH & Type 2 #Diabetes was associated w/ improvements in some non-invasive fibrosis markers. Check out our #TLMdX poster (1191) for more. #livertwitter ow.ly/KXF550GMskc

How did our main candidate HTD1801 (Berberine Ursodeoxycholate) perform in patients w/ Primary Sclerosing Cholangitis (#PSC) not previously exposed to UDCA? #TLMdX AASLD #livertwitter ow.ly/uCbQ50GMlGh

Liver fat content w/ HTD1801 (Berberine Ursodeoxycholate) closely associated with improved glycemic control, weight loss & reduced ALT in patients w/ #NASH? #TLMdX AASLD #livertwitter ow.ly/AHXy50GMs1e

Great news! Our oral presentation about HTD1801 results in patients w/ #NASH & #diabetes has been selected as one of the ‘Best of The Liver Meeting’ 2021 by AASLD! Exciting to see the data showcased during closing remarks today. #TLMdX #livertwitter x.com/HighTideThera/…

Thank you Ruth-Anne Pai, PhD for highlighting the excellent session Emerging Therapies for #PSC & #PBC. Thanks to Cynthia Levy, MD & @AutoImmuneLiver. #LiverMtg21 AASLD EASLnews @PSCPartners PSC Partners Canada PSC Support PSC Support Australia European Liver Patients' Association ERN RARE LIVER ABGH

Very honored to be in this lineup of brilliant women, summarizing the inspiring work of our community! What a meeting! Carla Brady @Duke_liverdoc AASLD AASLD President

Congratulations to our Director, Dr. Lorne Tyrrell, on receiving Hep B Foundation's 2022 Blumberg Prize for his pioneering work on hepatitis B!

Thank you Nature Reviews Gastroenterology & Hepatology for highlighting our paper on #NASH drugs. Mazen Noureddin, MD, MHSc @RajVlanchi Adrian Di Bisceglie Jonathan G. Stine, MD MSc, FACP Pinnacle Clinical Research Arizona Liver Health Madrigal Pharmaceuticals Novo Nordisk US Intercept Pharma Inventiva Pharma

If you want to know how it’s going in the ER, last night I saw more patients than I’ve ever seen in a single night shift in my entire career. And I’ve been out of residency since 2005, working only night shifts since 2006.

Why does our ID have to be scanned at every room AASLD at the liver meeting? Are we being tracked? Delays entry to rooms. What happens to these data? #lossofprivacy #bigbrother #TLM